Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680300 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HPGDPOLBKMT2A | |
| SCHEMBL15434035 | 0.82 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2HPGDKMT2ARXFP1 | |
| SCHEMBL3678080 | 0.74 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2HPGDKMT2AHTT | |
| SCHEMBL7130005 | 0.73 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDPOLBKMT2A | |
| SCHEMBL31570092 | 0.73 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDPOLBKMT2A | |
| SCHEMBL21765855 | 0.70 | HTT (0.72) | ALDH1A1SMN1; SMN2POLBKMT2AHTT | |
| SCHEMBL3309810 | 0.70 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDPOLBKMT2A | |
| SCHEMBL14267041 | 0.70 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HPGDKMT2AKDM4E | |
| SCHEMBL4187570 | 0.69 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2HPGDPOLBKMT2A | |
| SCHEMBL4216922 | 0.68 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2POLBKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922074-B1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA. | ASTRAZENECA AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20080194632-A1 | Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1922070-A1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007024183-A1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | NR3C1, NR3C2, CHRM3 | ALDH1A1 876/4885SMN1; SMN2 3812/4885HPGD 373/4885 |
| US-20080194632-A1 | Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases | ACKR3, CCR5, CCR2 | ALDH1A1 809/4885SMN1; SMN2 3256/4885HPGD 377/4885 |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ADRB2, ADRB1, CHRM2 | ALDH1A1 1195/4885SMN1; SMN2 2762/4885HPGD 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.